Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges
For over two decades, the development of B-cell lymphoma-2 (Bcl-2) family therapeutics has primarily focused on anti-apoptotic proteins, resulting in the first-in-class drugs called BH3 mimetics, especially for Bcl-2 inhibitor Venetoclax. The pro-apoptotic protein Bcl-2-associated X protein (BAX) pl...
Shranjeno v:
Main Authors: | , , , , , |
---|---|
Format: | Knjiga |
Izdano: |
Elsevier,
2024-06-01T00:00:00Z.
|
Teme: | |
Online dostop: | Connect to this object online. |
Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Kopija 1 | Prosto |